A strategy to design protein-based antagonists against type I cytokine receptors
PLOS Biology · 2024
DOI: 10.1371/journal.pbio.3002883 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Biology, 2024. Verfasst von Timo Ullrich und 12 weiteren Autor:innen. Beteiligte Einrichtung: Max Planck Institute for Biology, Department of Protein Evolution, Tübingen, Germany. Hauptthemen laut MEDLINE: Receptors, Granulocyte Colony-Stimulating Factor. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft (DFG), José Carreras Leukämie-Stiftung, M. Schickedanz Kinderkrebsstiftung.
Abstract (Originalsprache)
Excessive cytokine signaling resulting from dysregulation of a cytokine or its receptor can be a main driver of cancer, autoimmune, or hematopoietic disorders. Here, we leverage protein design to create tailored cytokine receptor blockers with idealized properties. Specifically, we aimed to tackle the granulocyte-colony stimulating factor receptor (G-CSFR), a mediator of different types of leukemia and autoinflammatory diseases. By modifying designed G-CSFR binders, we engineered hyper-stable proteins that function as nanomolar signaling antagonists. X-ray crystallography showed atomic-level agreement with the experimental structure of an exemplary design. Furthermore, the most potent design blocks G-CSFR in acute myeloid leukemia cells and primary human hematopoietic stem cells. Thus, the resulting designs can be used for inhibiting or homing to G-CSFR-expressing cells. Our results also demonstrate that similarly designed cytokine mimics can be used to derive antagonists to tackle other type I cytokine receptors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Max Planck Institute for Biology, Department of Protein Evolution, Tübingen, Germany.
- Translational Oncology, Internal Medicine II, University Hospital Tübingen, Tübingen, Germany.
- Department of Biology/Chemistry and Center for Cellular Nanoanalytics, Osnabrück University, Osnabrück, Germany.
- Interfaculty Institute of Biochemistry, University of Tübingen, Tübingen, Germany.
ORCID-Profile: Mohammad ElGamacy
Förderung
- Deutsche Forschungsgemeinschaft (DFG)
- José Carreras Leukämie-Stiftung
- M. Schickedanz Kinderkrebsstiftung
- Max-Planck-Gesellschaft
Zitieren
APA
Ullrich, T., Klimenkova, O., Pollmann, C., Lasram, A., Hatskovska, V., Maksymenko, K., Milijaš-Jotić, M., Schenk, L., Lengerke, C., Hartmann, M. D., Piehler, J., Skokowa, J., & ElGamacy, M. (2024). A strategy to design protein-based antagonists against type I cytokine receptors. PLOS Biology. https://doi.org/10.1371/journal.pbio.3002883
Vancouver
Ullrich T, Klimenkova O, Pollmann C, Lasram A, Hatskovska V, Maksymenko K, et al. A strategy to design protein-based antagonists against type I cytokine receptors. PLOS Biology. 2024. doi:10.1371/journal.pbio.3002883
BibTeX
@article{Ullrich2024,
author = {Ullrich, Timo and Klimenkova, Olga and Pollmann, Christoph and Lasram, Asma and Hatskovska, Valeriia and Maksymenko, Kateryna and Milijaš-Jotić, Matej and Schenk, Lukas and Lengerke, Claudia and Hartmann, Marcus D and Piehler, Jacob and Skokowa, Julia and ElGamacy, Mohammad},
title = {A strategy to design protein-based antagonists against type I cytokine receptors},
journal = {PLOS Biology},
year = {2024},
doi = {10.1371/journal.pbio.3002883}
}
EUVIMED